Chronic Inflammatory Demyelinating Polyneuropathy

Autoimmune MONDO:0006702 Pathograph 7 Autoimmune Disease Peripheral Neuropathy

A chronic acquired immune-mediated neuropathy characterized by progressive or relapsing-remitting symmetric proximal and distal weakness with sensory involvement. Distinguished from GBS by duration greater than 8 weeks and chronic course.

Ask OpenScientist

Ask a research question about Chronic Inflammatory Demyelinating Polyneuropathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Pathophys.
4
Phenotypes
7
Pathograph
5
Medical Actions
6
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
NEUROLOGIC IMMUNE_RHEUMATOLOGIC
⚙

Pathophysiology

3
T Cell-Mediated Demyelination
CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to demyelination. T cells recognize myelin antigens and produce inflammatory cytokines that damage Schwann cells.
CD4+ T Cell CL:0000624 CD8+ T Cell CL:0000625
Adaptive Immune Response GO:0002250
Show evidence (1 reference)
PMID:37356965 PARTIAL
"Autoimmune neuropathies are a heterogeneous group of rare and disabling diseases in which the immune system is thought to target antigens in the peripheral nervous system: they usually respond to immune therapies."
This pathology review confirms that CIDP involves immune-mediated targeting of peripheral nerve antigens, supporting the role of adaptive immunity including T cell responses in disease pathogenesis.
Antibody and Complement-Mediated Damage
Autoantibodies against myelin proteins and nodal/paranodal antigens (neurofascin, contactin-1) contribute to demyelination. Complement deposition amplifies nerve damage.
Complement Activation GO:0006956 Immunoglobulin Production GO:0002377
Show evidence (2 references)
PMID:35378684 SUPPORT
"The complement system appears to play a role in promoting macrophage-mediated demyelination."
This review establishes the role of complement activation in CIDP pathogenesis, linking complement to the amplification of macrophage-mediated nerve damage.
PMID:36346134 SUPPORT
"Besides IgG4, subclass IgG3 was detected and associated with complement binding and cytotoxic effects in vitro."
Experimental evidence showing that IgG3 subclass antibodies activate complement, demonstrating complement-mediated pathogenic mechanisms in autoantibody-positive CIDP.
Macrophage-Mediated Myelin Stripping
Activated macrophages invade nerve fibers and actively strip myelin from axons, causing segmental demyelination visible on nerve biopsy.
Macrophage CL:0000235
Inflammatory Response GO:0006954
Show evidence (2 references)
PMID:37356965 PARTIAL
"In contrast, the mechanisms of demyelination of other dysimmune neuropathies induced by macrophages are unexplained, as no antibodies have been identified in such cases."
This pathology review acknowledges macrophage-induced demyelination as a distinct mechanism in CIDP, occurring even in cases without identified autoantibodies, supporting the role of innate immune responses independent of antibody-mediated damage.
PMID:36645654 PARTIAL
"The proposed mechanisms of action of IVIg that can mediate its therapeutic effects are reviewed. These include anti-idiotypic interactions, inhibition of neonatal Fc receptors (FcRn), anti-complement activity, upregulation of inhibitory FcγRIIB receptors, and downregulation of macrophage activation."
IVIg therapy works in part by downregulating macrophage activation, providing indirect evidence that macrophages play a central pathogenic role in CIDP that can be therapeutically targeted.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Chronic Inflammatory Demyelinating Polyneuropathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Limbs 1
Progressive Weakness VERY_FREQUENT Limb muscle weakness HP:0003690
Symmetric, proximal and distal
Show evidence (1 reference)
DOI:10.3389/fimmu.2025.1575464 SUPPORT
"Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disease of the peripheral nerves characterized by proximal and distal muscle weakness and sensory abnormalities."
The review supports proximal and distal weakness as a defining CIDP clinical feature.
Nervous System 2
Areflexia VERY_FREQUENT Areflexia HP:0001284
Show evidence (1 reference)
PMID:29512576 SUPPORT Human Clinical
"Salient features on examintion were: distal weakness (10), proximal weakness (6), impaired touch and pain (12), impaired joint position and vibration sense (6), distal areflexia (12), bilateral impaired hearing (2) and thickened nerves (4)."
This CIDP clinical series directly reports distal areflexia among salient examination findings.
Sensory Loss FREQUENT Sensory neuropathy HP:0000763
Show evidence (1 reference)
PMID:38330421 SUPPORT
"Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired, chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy that had progressed for >2 months."
This clinical study establishes sensory polyneuropathy as a diagnostic criterion and key phenotype of sensory CIDP variant, demonstrating that sensory loss is a prominent and treatable feature in CIDP.
Constitutional 1
Fatigue FREQUENT Fatigue HP:0012378
Show evidence (2 references)
PMID:35357725 SUPPORT
"Pain, depression and fatigue are relevant disability factors in CIDP affecting quality of life."
The prospective INHIBIT registry study supports fatigue as a relevant CIDP disability factor.
PMID:23852276 SUPPORT Human Clinical
"Frequently occurring and often disabling symptoms in CIDP such as fatigue, pain and tremor have recently been emphasised, whereas autonomic dysfunction, if present, is usually mild."
This review independently supports fatigue as a commonly disabling CIDP symptom and uses the previously cached PMID.
💊

Medical Actions

5
IVIG
Action: intravenous immunoglobulin therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: human immunoglobulin G NCIT:C80829
First-line therapy for most patients.
Mechanism Target:
MODULATES T Cell-Mediated Demyelination — IVIG modulates T cell function via Fc receptor saturation and anti-idiotypic antibody effects, dampening autoreactive T cell attack on peripheral myelin.
INHIBITS Antibody and Complement-Mediated Damage — IVIG inhibits complement activation and blocks Fc-receptor-mediated macrophage activation, reducing antibody-driven demyelination and complement-mediated paranodal membrane damage.
Show evidence (1 reference)
PMID:40720971 SUPPORT
"The recommended treatment strategies include first-line therapies such as corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis, with guidance on escalation and titration of immunosuppressive therapy in refractory cases."
The consensus recommendation lists IVIG among first-line CIDP therapies.
Corticosteroids
Action: corticosteroid agent therapy MAXO:0000640
Agent: corticosteroid CHEBI:50858
Alternative first-line therapy.
Mechanism Target:
INHIBITS T Cell-Mediated Demyelination — Corticosteroids suppress autoreactive T cell proliferation and cytokine release, reducing T cell-driven demyelination of peripheral nerve myelin.
INHIBITS Antibody and Complement-Mediated Damage — Corticosteroids reduce B cell autoantibody production and suppress complement-mediated damage to the nodal and paranodal structures.
Show evidence (1 reference)
PMID:40720971 SUPPORT
"The recommended treatment strategies include first-line therapies such as corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis, with guidance on escalation and titration of immunosuppressive therapy in refractory cases."
The consensus recommendation lists corticosteroids among first-line CIDP therapies.
Plasmapheresis
Action: plasma exchange Ontology label: Plasmapheresis NCIT:C15304
For refractory cases or acute exacerbations.
Mechanism Target:
INHIBITS Antibody and Complement-Mediated Damage — Plasmapheresis removes pathogenic autoantibodies (anti-neurofascin, anti-contactin-1, and others) from the circulation, reducing the antibody load targeting nodal and paranodal peripheral nerve structures.
Show evidence (1 reference)
PMID:40720971 SUPPORT
"The recommended treatment strategies include first-line therapies such as corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis, with guidance on escalation and titration of immunosuppressive therapy in refractory cases."
The consensus recommendation lists plasmapheresis among first-line CIDP treatment strategies.
Rituximab
Action: rituximab therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: rituximab NCIT:C1702
For antibody-positive refractory cases.
Mechanism Target:
INHIBITS Antibody and Complement-Mediated Damage — Rituximab depletes CD20+ B cells, reducing the source of pathogenic autoantibodies (anti-neurofascin-155, anti-contactin-1) that mediate complement-dependent paranodal demyelination in CIDP.
Show evidence (1 reference)
DOI:10.3389/fimmu.2024.1475478 SUPPORT
"Plasma exchange and rituximab treatment led to a serological remission and corresponding significant clinical improvement, and the therapy was paused."
The autoimmune nodopathy case supports rituximab use in antibody-associated refractory nodal/paranodal immune neuropathy.
Efgartigimod
Action: FcRn antagonist therapy Ontology label: Pharmacotherapy NCIT:C15986
FcRn blocker approved for CIDP treatment, reducing pathogenic IgG exposure through neonatal Fc receptor blockade.
Mechanism Target:
INHIBITS Antibody and Complement-Mediated Damage — Efgartigimod blocks FcRn, accelerating IgG catabolism and reducing circulating pathogenic autoantibody levels that mediate complement-dependent demyelination at nodal and paranodal sites.
Show evidence (1 reference)
DOI:10.3389/fimmu.2025.1575464 SUPPORT Human Clinical
"The neonatal Fc receptor (FcRn) has also been targeted as a promising treatment avenue due to its role in immunoglobulin G degradation. Efgartigimod is the first FcRn blocker approved for the treatment of CIDP."
The review directly documents efgartigimod as an approved FcRn-blocking CIDP treatment.
🔬

Biochemical Markers

3
CSF Protein (Elevated)
Context: Without pleocytosis
Show evidence (1 reference)
DOI:10.69622/28457924.v1 SUPPORT
"In CIDP, levels of BTP were elevated in both CSF and plasma, while in GBS only in CSF."
This biomarker study supports CSF protein abnormalities in CIDP.
Anti-Neurofascin Antibodies (Variable)
Context: Associated with specific CIDP subtype
Show evidence (1 reference)
DOI:10.1093/brain/awac418 SUPPORT
"Autoimmune neuropathy associated with antibodies against pan-neurofascin is a new subtype of nodo-paranodopathy."
This study supports anti-neurofascin antibodies as biomarkers of a nodo-paranodal immune neuropathy overlapping CIDP-spectrum classification.
Anti-Contactin-1 Antibodies (Variable)
Context: Associated with specific CIDP subtype
Show evidence (1 reference)
DOI:10.3389/fimmu.2024.1475478 SUPPORT
"Anti-contactin-1 IgG2 antibodies were detected, and the diagnosis was reverted to AN."
The autoimmune nodopathy case supports anti-contactin-1 antibodies as clinically relevant nodal/paranodal autoantibodies.
{ }

Source YAML

click to show 
name: Chronic Inflammatory Demyelinating Polyneuropathy
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-02-17T21:53:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Peripheral Neuropathy
disease_term:
  preferred_term: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  term:
    id: MONDO:0006702
    label: chronic inflammatory demyelinating polyradiculoneuropathy
description: >-
  A chronic acquired immune-mediated neuropathy characterized by progressive
  or relapsing-remitting symmetric proximal and distal weakness with sensory
  involvement. Distinguished from GBS by duration greater than 8 weeks and
  chronic course.
pathophysiology:
- name: T Cell-Mediated Demyelination
  description: >-
    CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to
    demyelination. T cells recognize myelin antigens and produce inflammatory
    cytokines that damage Schwann cells.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:37356965
    reference_title: "Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies."
    supports: PARTIAL
    snippet: >-
      Autoimmune neuropathies are a heterogeneous group of rare and disabling diseases
      in which the immune system is thought to target antigens in the peripheral
      nervous system: they usually respond to immune therapies.
    explanation: >-
      This pathology review confirms that CIDP involves immune-mediated targeting
      of peripheral nerve antigens, supporting the role of adaptive immunity including
      T cell responses in disease pathogenesis.
- name: Antibody and Complement-Mediated Damage
  description: >-
    Autoantibodies against myelin proteins and nodal/paranodal antigens
    (neurofascin, contactin-1) contribute to demyelination. Complement
    deposition amplifies nerve damage.
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:35378684
    reference_title: "The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies."
    supports: SUPPORT
    snippet: >-
      The complement system appears to play a role in promoting macrophage-mediated
      demyelination.
    explanation: >-
      This review establishes the role of complement activation in CIDP pathogenesis,
      linking complement to the amplification of macrophage-mediated nerve damage.
  - reference: PMID:36346134
    reference_title: "Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage."
    supports: SUPPORT
    snippet: >-
      Besides IgG4, subclass IgG3 was detected and associated with complement binding
      and cytotoxic effects in vitro.
    explanation: >-
      Experimental evidence showing that IgG3 subclass antibodies activate complement,
      demonstrating complement-mediated pathogenic mechanisms in autoantibody-positive
      CIDP.
- name: Macrophage-Mediated Myelin Stripping
  description: >-
    Activated macrophages invade nerve fibers and actively strip myelin from
    axons, causing segmental demyelination visible on nerve biopsy.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:37356965
    reference_title: "Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies."
    supports: PARTIAL
    snippet: >-
      In contrast, the mechanisms of demyelination of other dysimmune neuropathies
      induced by macrophages are unexplained, as no antibodies have been identified
      in such cases.
    explanation: >-
      This pathology review acknowledges macrophage-induced demyelination as a distinct
      mechanism in CIDP, occurring even in cases without identified autoantibodies,
      supporting the role of innate immune responses independent of antibody-mediated
      damage.
  - reference: PMID:36645654
    reference_title: "Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations."
    supports: PARTIAL
    snippet: >-
      The proposed mechanisms of action of IVIg that can mediate its therapeutic effects
      are reviewed. These include anti-idiotypic interactions, inhibition of neonatal
      Fc
      receptors (FcRn), anti-complement activity, upregulation of inhibitory FcγRIIB
      receptors, and downregulation of macrophage activation.
    explanation: >-
      IVIg therapy works in part by downregulating macrophage activation, providing
      indirect
      evidence that macrophages play a central pathogenic role in CIDP that can be
      therapeutically
      targeted.
phenotypes:
- name: Progressive Weakness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limb Muscle Weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  notes: Symmetric, proximal and distal
  evidence:
  - reference: DOI:10.3389/fimmu.2025.1575464
    reference_title: A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy
    supports: SUPPORT
    snippet: >-
      Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
      immune-mediated disease of the peripheral nerves characterized by proximal
      and distal muscle weakness and sensory abnormalities.
    explanation: >-
      The review supports proximal and distal weakness as a defining CIDP
      clinical feature.
- name: Areflexia
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:29512576
    reference_title: "Chronic inflammatory demyelinating polyneuropathy : clinical, electrophysiological and morphological study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Salient features on examintion were: distal weakness (10), proximal
      weakness (6), impaired touch and pain (12), impaired joint position and
      vibration sense (6), distal areflexia (12), bilateral impaired hearing
      (2) and thickened nerves (4).
    explanation: >-
      This CIDP clinical series directly reports distal areflexia among salient
      examination findings.
- name: Sensory Loss
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Peripheral Sensory Neuropathy
    term:
      id: HP:0000763
      label: Sensory neuropathy
  evidence:
  - reference: PMID:38330421
    reference_title: "Sensory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Neglected Immunotherapy-Responsive Sensory Neuropathy."
    supports: SUPPORT
    snippet: >-
      Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired,
      chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy
      that had progressed for >2 months.
    explanation: >-
      This clinical study establishes sensory polyneuropathy as a diagnostic criterion
      and key phenotype of sensory CIDP variant, demonstrating that sensory loss is
      a
      prominent and treatable feature in CIDP.
- name: Fatigue
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:35357725
    reference_title: "Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: Results from the German INHIBIT registry."
    supports: SUPPORT
    snippet: >-
      Pain, depression and fatigue are relevant disability factors in CIDP
      affecting quality of life.
    explanation: >-
      The prospective INHIBIT registry study supports fatigue as a relevant CIDP
      disability factor.
  - reference: PMID:23852276
    reference_title: "Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequently occurring and often disabling symptoms in CIDP such as fatigue,
      pain and tremor have recently been emphasised, whereas autonomic dysfunction,
      if present, is usually mild.
    explanation: >-
      This review independently supports fatigue as a commonly disabling CIDP
      symptom and uses the previously cached PMID.
biochemical:
- name: CSF Protein
  presence: Elevated
  context: Without pleocytosis
  evidence:
  - reference: DOI:10.69622/28457924.v1
    reference_title: Biomarker and pathogenic study of immune-mediated neuropathies
    supports: SUPPORT
    snippet: >-
      In CIDP, levels of BTP were elevated in both CSF and plasma, while in GBS
      only in CSF.
    explanation: >-
      This biomarker study supports CSF protein abnormalities in CIDP.
- name: Anti-Neurofascin Antibodies
  presence: Variable
  context: Associated with specific CIDP subtype
  evidence:
  - reference: DOI:10.1093/brain/awac418
    reference_title: Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage
    supports: SUPPORT
    snippet: >-
      Autoimmune neuropathy associated with antibodies against pan-neurofascin is
      a new subtype of nodo-paranodopathy.
    explanation: >-
      This study supports anti-neurofascin antibodies as biomarkers of a
      nodo-paranodal immune neuropathy overlapping CIDP-spectrum classification.
- name: Anti-Contactin-1 Antibodies
  presence: Variable
  context: Associated with specific CIDP subtype
  evidence:
  - reference: DOI:10.3389/fimmu.2024.1475478
    reference_title: "Case report: target antigen and subclass switch in a patient with autoimmune nodopathy"
    supports: SUPPORT
    snippet: >-
      Anti-contactin-1 IgG2 antibodies were detected, and the diagnosis was
      reverted to AN.
    explanation: >-
      The autoimmune nodopathy case supports anti-contactin-1 antibodies as
      clinically relevant nodal/paranodal autoantibodies.
treatments:
- name: IVIG
  description: First-line therapy for most patients.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: human immunoglobulin G
      term:
        id: NCIT:C80829
        label: Human Immunoglobulin G
  evidence:
  - reference: PMID:40720971
    reference_title: "Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)."
    supports: SUPPORT
    snippet: >-
      The recommended treatment strategies include first-line therapies such as
      corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis,
      with guidance on escalation and titration of immunosuppressive therapy in
      refractory cases.
    explanation: >-
      The consensus recommendation lists IVIG among first-line CIDP therapies.
  target_mechanisms:
  - target: T Cell-Mediated Demyelination
    treatment_effect: MODULATES
    description: >-
      IVIG modulates T cell function via Fc receptor saturation and anti-idiotypic
      antibody effects, dampening autoreactive T cell attack on peripheral myelin.
  - target: Antibody and Complement-Mediated Damage
    treatment_effect: INHIBITS
    description: >-
      IVIG inhibits complement activation and blocks Fc-receptor-mediated
      macrophage activation, reducing antibody-driven demyelination and
      complement-mediated paranodal membrane damage.
- name: Corticosteroids
  description: Alternative first-line therapy.
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: MAXO:0000640
      label: corticosteroid agent therapy
    therapeutic_agent:
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  evidence:
  - reference: PMID:40720971
    reference_title: "Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)."
    supports: SUPPORT
    snippet: >-
      The recommended treatment strategies include first-line therapies such as
      corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis,
      with guidance on escalation and titration of immunosuppressive therapy in
      refractory cases.
    explanation: >-
      The consensus recommendation lists corticosteroids among first-line CIDP
      therapies.
  target_mechanisms:
  - target: T Cell-Mediated Demyelination
    treatment_effect: INHIBITS
    description: >-
      Corticosteroids suppress autoreactive T cell proliferation and cytokine
      release, reducing T cell-driven demyelination of peripheral nerve myelin.
  - target: Antibody and Complement-Mediated Damage
    treatment_effect: INHIBITS
    description: >-
      Corticosteroids reduce B cell autoantibody production and suppress
      complement-mediated damage to the nodal and paranodal structures.
- name: Plasmapheresis
  description: For refractory cases or acute exacerbations.
  treatment_term:
    preferred_term: plasma exchange
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  evidence:
  - reference: PMID:40720971
    reference_title: "Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)."
    supports: SUPPORT
    snippet: >-
      The recommended treatment strategies include first-line therapies such as
      corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis,
      with guidance on escalation and titration of immunosuppressive therapy in
      refractory cases.
    explanation: >-
      The consensus recommendation lists plasmapheresis among first-line CIDP
      treatment strategies.
  target_mechanisms:
  - target: Antibody and Complement-Mediated Damage
    treatment_effect: INHIBITS
    description: >-
      Plasmapheresis removes pathogenic autoantibodies (anti-neurofascin,
      anti-contactin-1, and others) from the circulation, reducing the
      antibody load targeting nodal and paranodal peripheral nerve structures.
- name: Rituximab
  description: For antibody-positive refractory cases.
  treatment_term:
    preferred_term: rituximab therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  evidence:
  - reference: DOI:10.3389/fimmu.2024.1475478
    reference_title: "Case report: target antigen and subclass switch in a patient with autoimmune nodopathy"
    supports: SUPPORT
    snippet: >-
      Plasma exchange and rituximab treatment led to a serological remission and
      corresponding significant clinical improvement, and the therapy was paused.
    explanation: >-
      The autoimmune nodopathy case supports rituximab use in antibody-associated
      refractory nodal/paranodal immune neuropathy.
  target_mechanisms:
  - target: Antibody and Complement-Mediated Damage
    treatment_effect: INHIBITS
    description: >-
      Rituximab depletes CD20+ B cells, reducing the source of pathogenic
      autoantibodies (anti-neurofascin-155, anti-contactin-1) that mediate
      complement-dependent paranodal demyelination in CIDP.
- name: Efgartigimod
  description: >-
    FcRn blocker approved for CIDP treatment, reducing pathogenic IgG exposure
    through neonatal Fc receptor blockade.
  treatment_term:
    preferred_term: FcRn antagonist therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: DOI:10.3389/fimmu.2025.1575464
    reference_title: A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The neonatal Fc receptor (FcRn) has also been targeted as a promising
      treatment avenue due to its role in immunoglobulin G degradation.
      Efgartigimod is the first FcRn blocker approved for the treatment of
      CIDP.
    explanation: >-
      The review directly documents efgartigimod as an approved FcRn-blocking
      CIDP treatment.
  target_mechanisms:
  - target: Antibody and Complement-Mediated Damage
    treatment_effect: INHIBITS
    description: >-
      Efgartigimod blocks FcRn, accelerating IgG catabolism and reducing
      circulating pathogenic autoantibody levels that mediate
      complement-dependent demyelination at nodal and paranodal sites.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: DOI:10.3389/fimmu.2025.1575464
      reference_title: A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy
      supports: SUPPORT
      snippet: >-
        Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
        immune-mediated disease of the peripheral nerves characterized by proximal
        and distal muscle weakness and sensory abnormalities.
      explanation: >-
        Peripheral nerve disease with weakness supports neurological classification.
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:40720971
      reference_title: "Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)."
      supports: SUPPORT
      snippet: >-
        Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
        acquired autoimmune disorder that leads to progressive motor and sensory
        impairment, resulting in significant morbidity.
      explanation: >-
        The consensus recommendation explicitly classifies CIDP as acquired and
        autoimmune.
references:
- reference: DOI:10.1111/bpa.13184
  title: Pathology explains various mechanisms of auto‐immune inflammatory peripheral neuropathies
  found_in:
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-cyberian-codex.md
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fimmu.2024.1475478
  title: 'Case report: target antigen and subclass switch in a patient with autoimmune nodopathy'
  found_in:
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-cyberian-codex.md
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fimmu.2025.1575464
  title: A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy
  found_in:
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-cyberian-codex.md
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-falcon.md
  findings: []
- reference: DOI:10.69622/28457924.v1
  title: Biomarker and pathogenic study of immune-mediated neuropathies
  found_in:
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-cyberian-codex.md
  - Chronic_Inflammatory_Demyelinating_Polyneuropathy-deep-research-falcon.md
  findings: []
- reference: PMID:23852276
  title: "Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options."
  findings: []
- reference: PMID:29512576
  title: "Chronic inflammatory demyelinating polyneuropathy : clinical, electrophysiological and morphological study."
  findings: []
📚

References & Deep Research

References

6
DOI:10.1111/bpa.13184
Pathology explains various mechanisms of auto‐immune inflammatory peripheral neuropathies
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1475478
Case report: target antigen and subclass switch in a patient with autoimmune nodopathy
No top-level findings curated for this source.
DOI:10.3389/fimmu.2025.1575464
A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy
No top-level findings curated for this source.
DOI:10.69622/28457924.v1
Biomarker and pathogenic study of immune-mediated neuropathies
No top-level findings curated for this source.
PMID:23852276
Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options.
No top-level findings curated for this source.
PMID:29512576
Chronic inflammatory demyelinating polyneuropathy : clinical, electrophysiological and morphological study.
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Chronic Inflammatory Demyelinating Polyneuropathy
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 10

Key Pathophysiology Nodes

  • T Cell-Mediated Demyelination
  • Antibody and Complement-Mediated Damage
  • Macrophage-Mediated Myelin Stripping
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1111/bpa.13184
  • DOI:10.3389/fimmu.2024.1475478
  • DOI:10.3389/fimmu.2025.1575464
  • DOI:10.69622/28457924.v1
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 22 citations 2025-12-18T09:54:28.294218

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • MONDO ID: not definitively assigned for the entire CIDP spectrum in sources cited here
  • Category: Autoimmune

Pathophysiology Description (current understanding)

CIDP is an immune-mediated disorder of peripheral nerves characterized by heterogeneous, overlapping mechanisms that variably involve cellular immunity (T cells, macrophages), humoral autoimmunity (B cells, autoantibodies), complement activation, and disruption of the blood–nerve barrier (BNB). Pathology classically shows macrophage-mediated segmental demyelination, with inflammatory infiltrates of T cells and macrophages within endoneurium; humoral mechanisms are supported by immunoglobulin deposition and, in defined subgroups, pathogenic autoantibodies against nodal/paranodal proteins that disrupt axo–glial junctions without prominent inflammation. Complement activation (including terminal C5b-9 deposition) appears to promote demyelination and correlates with inflammatory cell infiltration and severity in biopsy cohorts. Therapeutic responsiveness to IVIg, corticosteroids, and plasma exchange underscores antibody and immune effector contributions, while newer strategies—FcRn blockade and complement inhibition—further link specific pathways to disease activity. Overall, CIDP encompasses at least two mechanistic archetypes: (1) macrophage/complement-driven segmental demyelination; and (2) nodal/paranodal autoantibody-mediated “autoimmune nodopathies,” now defined as distinct from classical CIDP, with unique treatment implications. (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 1-2, caballeroavila2025apathophysiologicaland pages 5-6, caballeroavila2025apathophysiologicaland pages 2-3)

Mechanism/Process Key molecules (HGNC) Cell types (CL) Cellular components (GO-CC) Biological processes (GO-BP) Evidence & year (PMID/DOI, URL)
Macrophage-mediated segmental demyelination Fc gamma receptors (FCGRs, e.g., FCGR3A); myelin proteins (e.g., MPZ, PMP22) Macrophage (CL: macrophage), Schwann cell (CL: Schwann cell) Myelin sheath (GO:0043209); endoneurium Macrophage-mediated phagocytosis of myelin; segmental demyelination (vallat2024pathologyexplainsvarious pages 8-8) Vallat & Mathis 2024; DOI: 10.1111/bpa.13184; https://doi.org/10.1111/bpa.13184
T- and B-cell involvement (adaptive immunity) CD4 (CD4), CD8A (CD8A), CD20 (MS4A1), BAFF (TNFSF13B) CD4+ T cell, CD8+ T cell, B cell / plasma cell Immune synapse / lymphocyte plasma membrane (GO-CC) Antigen processing and presentation; T-cell cytotoxicity; B-cell antibody production (kmezic2025biomarkerandpathogenic pages 150-152, kmezic2025biomarkerandpathogenic pages 178-181) Kmezic 2025; DOI: 10.69622/28457924.v1; https://doi.org/10.69622/28457924.v1
Nodal/paranodal autoantibodies (autoimmune nodopathy) NFASC (isoforms NF155, NF186/140), CNTN1, CNTNAP1 (CASPR1) Schwann cell (paranodal glia), axonal paranode Node of Ranvier (GO:0033268); paranodal junction (GO-CC) Disruption of node/paranode assembly, loss of ion-channel clustering, conduction block (vallat2024pathologyexplainsvarious pages 8-8, appeltshauser2024casereporttarget pages 8-8) Vallat 2024; Appeltshauser 2024 (case report) DOI: 10.1111/bpa.13184, 10.3389/fimmu.2024.1475478
Complement activation (terminal pathway / MAC) Complement components C3, C5, membrane attack complex (C5b-9) Macrophages, endoneurial endothelial cells, Schwann cells Membrane attack complex (GO:0030442); endoneurial capillary Complement activation, opsonization, MAC-mediated membrane injury and promotion of demyelination (caballeroavila2025apathophysiologicaland pages 5-6, vallat2024pathologyexplainsvarious pages 8-8) Caballero-Ávila 2025 DOI: 10.3389/fimmu.2025.1575464; Vallat 2024 DOI: 10.1111/bpa.13184
Blood–nerve barrier (BNB) disruption / increased permeability Tight junction proteins (e.g., CLDN5), chemokines (e.g., CCLs) Peripheral nerve microvascular endothelial cell (CL), pericyte Blood–nerve barrier / tight junction (GO-CC) Increased vascular permeability, leukocyte extravasation into endoneurium (kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 29-35) Kmezic 2025 DOI: 10.69622/28457924.v1; (supporting BNB findings in related studies)
Fluid/serologic biomarkers (diagnostic/prognostic) NEFL (NfL), IL8 (IL-8), PTGDS (beta-trace protein) Neurons/axons (NEFL), immune cells (IL8), CSF-producing cells (PTGDS) Neuronal cytoskeleton (GO:0043227); extracellular region/CSF (GO:0005576) Axonal injury release (NfL); chemokine signaling (IL-8); CSF protein changes reflecting barrier dysfunction (beta-trace) (kmezic2025biomarkerandpathogenic pages 150-152, kmezic2025biomarkerandpathogenic pages 178-181) Kmezic 2025 DOI: 10.69622/28457924.v1 (NfL, IL-8, beta-trace validated in cohorts)
Therapeutic mechanisms (mechanism-linked interventions) IVIg (polyclonal IgG), FCGRT (FcRn target for efgartigimod), MS4A1 (CD20; rituximab), C5 / C1s (eculizumab / anti-complement agents) B cells / plasma cells (targeted by rituximab), FcR-expressing macrophages, endothelial cells Extracellular region; endosomal FcRn recycling compartment (GO-CC) IgG neutralization and Fc modulation (IVIg); immunosuppression (corticosteroids); antibody removal (PLEX); B-cell depletion (rituximab); IgG lowering via FcRn blockade (efgartigimod); complement blockade (anti-C5/anti-C1s) (caballeroavila2025apathophysiologicaland pages 5-6, kmezic2025biomarkerandpathogenic pages 178-181, appeltshauser2024casereporttarget pages 8-8) Caballero-Ávila 2025 DOI: 10.3389/fimmu.2025.1575464; Kmezic 2025 DOI: 10.69622/28457924.v1; Appeltshauser 2024 DOI: 10.3389/fimmu.2024.1475478

Table: Compact summary linking major CIDP mechanisms to molecules, cell types, cellular locations (GO-CC), processes (GO-BP) and recent evidence (context IDs, DOIs/URLs). Useful for ontology annotation and knowledge-base entry drafting.

1. Core Pathophysiology

  • Primary mechanisms
  • Macrophage-mediated demyelination: Endoneurial macrophages strip compact myelin, producing segmental demyelination and onion-bulb change; this is the signature lesion on nerve biopsy in many CIDP patients. (vallat2024pathologyexplainsvarious pages 8-8)
  • Adaptive immunity: CD4+ and CD8+ T cells infiltrate peripheral nerves; cytokine milieu suggests Th1/Th17 polarization; Schwann cells may upregulate antigen presentation molecules, sustaining local inflammation. (caballeroavila2025apathophysiologicaland pages 1-2, kmezic2025biomarkerandpathogenic pages 44-47)
  • Humoral autoimmunity at nodes/paranodes: Autoantibodies to neurofascin isoforms (NF155; nodal NF186/140), contactin-1 (CNTN1) and CASPR1 define autoimmune nodopathies, with disruption of paranodal septate junctions and conduction failure, often with poor response to IVIg but responsiveness to B cell–directed therapy. (vallat2024pathologyexplainsvarious pages 8-8)
  • Complement activation: Evidence includes deposition of terminal complement complex (C5b-9) on endoneurial microvessels and myelin, with proposed roles in opsonization and macrophage recruitment; motivates evaluation of complement inhibitors. (caballeroavila2025apathophysiologicaland pages 5-6, vallat2024pathologyexplainsvarious pages 8-8)
  • BNB disruption: Increased permeability allows immune cell ingress and antibody access to axo–glial targets, facilitating chronic inflammation. (kmezic2025biomarkerandpathogenic pages 29-35)
  • Dysregulated molecular pathways
  • Complement cascades (classical/alternative) converging on C3/C5 and MAC; IgG effector pathways engaging Fcγ receptors on phagocytes; FcRn-mediated IgG recycling as a regulator of IgG pool; cytokine/chemokine networks (e.g., IL-8) reflecting intrathecal inflammation. (caballeroavila2025apathophysiologicaland pages 5-6, kmezic2025biomarkerandpathogenic pages 178-181)
  • Affected cellular processes
  • Myelin phagocytosis, antigen presentation, lymphocyte activation, axo–glial junction assembly, and conduction at the node of Ranvier; secondary axonal degeneration with chronicity (elevated NfL). (vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 178-181)

2. Key Molecular Players

  • Genes/Proteins (HGNC)
  • NFASC (Neurofascin isoforms NF155 [Schwann cell], NF186/140 [axonal]): paranodal/nodal adhesion; autoantibody targets in autoimmune nodopathy. (vallat2024pathologyexplainsvarious pages 8-8)
  • CNTN1 (Contactin-1), CNTNAP1 (CASPR1): paranodal axoglial complex; autoantibody targets. (vallat2024pathologyexplainsvarious pages 8-8)
  • Complement components C3, C5; terminal complement complex C5b-9 (MAC): effector injury mechanisms and vascular deposition. (caballeroavila2025apathophysiologicaland pages 5-6)
  • FCGRT (FcRn): regulates IgG recycling and serum half-life; therapeutic target for IgG lowering. (caballeroavila2025apathophysiologicaland pages 5-6)
  • NEFL (Neurofilament light chain): axonal injury biomarker in CSF/plasma. (kmezic2025biomarkerandpathogenic pages 178-181)
  • IL8 (CXCL8): chemokine elevated in CIDP CSF; diagnostic/prognostic value. (kmezic2025biomarkerandpathogenic pages 178-181)
  • PTGDS (beta-trace protein): elevated in CIDP CSF; may outperform albumin quotient in some analyses. (kmezic2025biomarkerandpathogenic pages 150-152)
  • Chemical entities (CHEBI/drugs)
  • IVIg (polyclonal IgG), corticosteroids (glucocorticoids), plasma exchange (PLEX), rituximab (anti-CD20), efgartigimod (FcRn blocker), complement inhibitors (e.g., anti-C5, anti-C1s such as riliprubart). (caballeroavila2025apathophysiologicaland pages 5-6, appeltshauser2024casereporttarget pages 8-8)
  • Cell types (CL)
  • Macrophages (endoneurial), CD4+ T cells, CD8+ T cells, B cells/plasma cells, Schwann cells, endoneurial endothelial cells. (vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 44-47)
  • Anatomical locations (UBERON)
  • Peripheral nerve and nerve roots, sural nerve, node of Ranvier, paranode, blood–nerve barrier (endoneurial microvasculature). (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 5-6)

3. Biological Processes (GO terms)

  • Immune effector processes: complement activation (classical/alternative), Fc receptor signaling, leukocyte extravasation, cytokine-mediated signaling (e.g., IL-8). (caballeroavila2025apathophysiologicaland pages 5-6, kmezic2025biomarkerandpathogenic pages 178-181)
  • Myelin and conduction: axo–glial junction assembly, paranodal organization, myelin sheath maintenance, action potential propagation at nodes. (vallat2024pathologyexplainsvarious pages 8-8)
  • Phagocytosis and demyelination: macrophage-mediated myelin phagocytosis, segmental demyelination, antigen processing and presentation. (vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 44-47)
  • Axonal injury responses: cytoskeletal damage with neurofilament release. (kmezic2025biomarkerandpathogenic pages 178-181)

4. Cellular Components (GO-CC)

  • Node of Ranvier; paranodal junction; myelin sheath; endoneurial capillaries and BNB; membrane attack complex; endosomal FcRn recycling compartment. (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 5-6)

5. Disease Progression

  • Proposed sequence 1) Predisposition/triggers (e.g., HLA background, metabolic/infectious modifiers) → 2) BNB dysfunction with permeability changes → 3) Entry of autoreactive T cells, macrophages, and antibodies into endoneurium → 4a) Classical CIDP: opsonization and macrophage-mediated segmental demyelination with complement participation; 4b) Autoimmune nodopathy: IgG (frequently IgG4) against nodal/paranodal targets causing paranodal dissection and conduction failure with minimal inflammation → 5) Secondary axonal loss and chronic disability. (kmezic2025biomarkerandpathogenic pages 29-35, vallat2024pathologyexplainsvarious pages 8-8)
  • Stages/phases
  • Relapsing-remitting and progressive courses occur; early treatment prevents irreversible axonal degeneration. (caballeroavila2025apathophysiologicaland pages 1-2)

6. Phenotypic Manifestations (HP)

  • Symmetric proximal and distal weakness, sensory loss with sensory ataxia, tremor, areflexia; CSF cytoalbuminologic dissociation (elevated protein); variable conduction block and demyelinating features on NCS; nodopathy often shows tremor, sensory ataxia, younger onset, poor IVIg response, better rituximab response. (caballeroavila2025apathophysiologicaland pages 1-2, vallat2024pathologyexplainsvarious pages 8-8)

Current Applications and Real-World Implementations

  • Diagnostics and biomarkers
  • Testing for nodal/paranodal antibodies (NF155, NF186/140, CNTN1, CASPR1) is now integrated into clinical workflows for suspected nodopathies, directing therapy choices. (vallat2024pathologyexplainsvarious pages 8-8)
  • Fluid biomarkers: CSF/plasma NfL correlates with axonal injury; CSF IL-8 shows diagnostic/prognostic value; CSF beta-trace protein elevation may aid diagnosis independent of albumin quotient. (kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 150-152)
  • Therapeutics (mechanism-linked)
  • IVIg, corticosteroids, and PLEX remain first-line, consistent with antibody/immune effector mechanisms. (caballeroavila2025apathophysiologicaland pages 2-3)
  • Rituximab shows benefit in IgG4-seropositive nodopathy subsets (B-cell mediation). (appeltshauser2024casereporttarget pages 8-8)
  • FcRn blockade: efgartigimod lowers total IgG and reduces relapse risk; represents a targeted strategy against circulating pathogenic IgG. (caballeroavila2025apathophysiologicaland pages 5-6)
  • Complement pathway inhibition: early studies with anti-complement agents (e.g., riliprubart; anti-C5) reflect the role of complement in macrophage-mediated demyelination; mixed results emphasize need for biomarker-guided selection. (caballeroavila2025apathophysiologicaland pages 5-6)

Expert Opinions and Analysis

  • Contemporary reviews emphasize that CIDP is a clinicopathologic umbrella with mechanistic heterogeneity; understanding whether a given patient has macrophage/complement-driven demyelination versus nodal/paranodal antibody-mediated disruption is critical for precision therapy and explains differential responses to IVIg versus rituximab or FcRn/complement modulators. (caballeroavila2025apathophysiologicaland pages 1-2, caballeroavila2025apathophysiologicaland pages 2-3)
  • Pathology continues to be pivotal: the presence of macrophage clusters and segmental demyelination versus paranodal dissection without inflammation helps stratify mechanisms and likely therapeutic responses. (vallat2024pathologyexplainsvarious pages 8-8)

Relevant Statistics and Data (recent)

  • FcRn blockade: Phase-stage data summarized in 2025 review reported longer relapse-free proportions with efgartigimod vs comparator (e.g., 73.1% vs 46.4% at a key timepoint in Stage B of a large trial), supporting IgG-lowering efficacy in CIDP. (caballeroavila2025apathophysiologicaland pages 5-6)
  • Complement: Biopsy-based analyses report prominent C5b-9 deposition on endoneurial capillaries in most patients, correlating with inflammatory cell infiltration and clinical severity, supporting a complement-mediated component in a substantial subset. (caballeroavila2025apathophysiologicaland pages 5-6)
  • Biomarkers: CSF/plasma NfL elevated across immune-mediated neuropathies and associates with prognosis; CSF IL-8 validated as diagnostic/prognostic; beta-trace protein elevated in CIDP independent of albumin quotient. (kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 150-152)

Evidence Items with Citations (PMIDs/DOIs and URLs)

  • Pathology of macrophage-mediated demyelination and nodal/paranodal autoimmunity; conceptualization of nodopathies distinct from classical CIDP: Vallat & Mathis, Brain Pathology (2024), DOI: 10.1111/bpa.13184, https://doi.org/10.1111/bpa.13184. (vallat2024pathologyexplainsvarious pages 8-8)
  • Mechanistic and therapeutic review linking complement, FcRn, and immune pathways; FcRn blockade approval and trial outcomes; complement inhibitor development: Caballero-Ávila et al., Frontiers in Immunology (2025), DOI: 10.3389/fimmu.2025.1575464, https://doi.org/10.3389/fimmu.2025.1575464. (caballeroavila2025apathophysiologicaland pages 1-2, caballeroavila2025apathophysiologicaland pages 5-6, caballeroavila2025apathophysiologicaland pages 2-3)
  • Biomarkers in CIDP and immune neuropathies: elevated plasma/CSF NfL, IL‑8 in CSF as diagnostic/prognostic, and beta-trace protein in CIDP CSF; translational BNB insights: Kmezic (Thesis, 2025), DOI: 10.69622/28457924.v1, https://doi.org/10.69622/28457924.v1. (kmezic2025biomarkerandpathogenic pages 150-152, kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 29-35)
  • Autoimmune nodopathy case with antigen/subclass switch; rituximab responsiveness; NfL tracking: Appeltshauser et al., Frontiers in Immunology (2024), DOI: 10.3389/fimmu.2024.1475478, https://doi.org/10.3389/fimmu.2024.1475478. (appeltshauser2024casereporttarget pages 8-8)

Ontology Annotations (examples)

  • Genes/Proteins (HGNC): NFASC; CNTN1; CNTNAP1; C3; C5; FCGRT; NEFL; IL8; PTGDS. (caballeroavila2025apathophysiologicaland pages 5-6, vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 150-152)
  • Biological Processes (GO-BP): complement activation; macrophage-mediated phagocytosis; antigen processing and presentation; axo–glial junction assembly; chemokine-mediated signaling pathway; regulation of IgG catabolic process (FcRn). (caballeroavila2025apathophysiologicaland pages 5-6, vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 178-181)
  • Cellular Components (GO-CC): node of Ranvier; paranodal junction; myelin sheath; endoneurial capillary; membrane attack complex; endosomal recycling compartment (FcRn). (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 5-6)
  • Cell Types (CL): macrophage; CD4+ T cell; CD8+ T cell; B cell; Schwann cell; endothelial cell. (vallat2024pathologyexplainsvarious pages 8-8, kmezic2025biomarkerandpathogenic pages 44-47)
  • Anatomy (UBERON): peripheral nerve; sural nerve; blood–nerve barrier; node of Ranvier; paranode. (vallat2024pathologyexplainsvarious pages 8-8, caballeroavila2025apathophysiologicaland pages 5-6)
  • Chemicals (CHEBI): IVIg; glucocorticoids; rituximab; efgartigimod; eculizumab; riliprubart. (caballeroavila2025apathophysiologicaland pages 5-6, appeltshauser2024casereporttarget pages 8-8)

Direct quotes (selected)

  • “It has been shown that immunoglobulin G from the serum of about 30% of CIDP patients immunolabels nodes of Ranvier or paranodes of myelinated axons… In these cases, paranodal dissection develops in the absence of macrophage‑induced demyelination.” (Vallat & Mathis 2024) (vallat2024pathologyexplainsvarious pages 8-8)
  • “The complement pathway plays a key role in promoting macrophage‑mediated demyelination… The neonatal Fc receptor (FcRn) has also been targeted… Efgartigimod is the first FcRn blocker approved for the treatment of CIDP.” (Caballero‑Ávila et al. 2025) (caballeroavila2025apathophysiologicaland pages 5-6)
  • “IL‑8 in CSF is validated as a diagnostic biomarker for GBS and CIDP… beta‑trace protein… may serve as a more informative diagnostic biomarker than albumin [in CIDP].” (Kmezic 2025) (kmezic2025biomarkerandpathogenic pages 178-181, kmezic2025biomarkerandpathogenic pages 150-152)
  • “Plasma exchange and rituximab treatment led to a serological remission and corresponding significant clinical improvement” in anti‑paranodal autoimmune nodopathy. (Appeltshauser et al. 2024) (appeltshauser2024casereporttarget pages 8-8)

Limitations and open questions: Several mechanistic details remain unresolved in seronegative CIDP; the extent and clinical utility of complement profiling and antibody discovery beyond established nodal/paranodal targets require larger studies; biomarker cutoffs and implementation pathways continue to evolve.

References

  1. (vallat2024pathologyexplainsvarious pages 8-8): Jean‐Michel Vallat and Stéphane Mathis. Pathology explains various mechanisms of auto‐immune inflammatory peripheral neuropathies. Brain Pathology, Jun 2024. URL: https://doi.org/10.1111/bpa.13184, doi:10.1111/bpa.13184. This article has 22 citations and is from a domain leading peer-reviewed journal.

  2. (caballeroavila2025apathophysiologicaland pages 1-2): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.

  3. (caballeroavila2025apathophysiologicaland pages 5-6): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.

  4. (caballeroavila2025apathophysiologicaland pages 2-3): Marta Caballero-Ávila, Lorena Martin-Aguilar, Roger Collet-Vidiella, Luis Querol, and Elba Pascual-Goñi. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Frontiers in Immunology, Apr 2025. URL: https://doi.org/10.3389/fimmu.2025.1575464, doi:10.3389/fimmu.2025.1575464. This article has 6 citations and is from a peer-reviewed journal.

  5. (kmezic2025biomarkerandpathogenic pages 150-152): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.

  6. (kmezic2025biomarkerandpathogenic pages 178-181): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.

  7. (appeltshauser2024casereporttarget pages 8-8): Luise Appeltshauser, Helena Glenewinkel, Sophia Rohrbacher, Lena Wessely, Carmen Villmann, Claudia Sommer, and Kathrin Doppler. Case report: target antigen and subclass switch in a patient with autoimmune nodopathy. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1475478, doi:10.3389/fimmu.2024.1475478. This article has 4 citations and is from a peer-reviewed journal.

  8. (kmezic2025biomarkerandpathogenic pages 29-35): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.

  9. (kmezic2025biomarkerandpathogenic pages 44-47): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.